Medicon Valley Biomedical Newsletter

The Medicon Valley Biomedical Newsletter is intended for decision makers in pharmaceutical and biotech companies, investors and other professionals who wish to keep updated on business related activities in the Medicon Valley.

April

The Medicon Valley Biomedical Newsletter April edition is brought to you by Region Skåne and Copenhagen Capacity. The top story this month is that MycoTeq has raised money for development of new antibiotics.

Find more information about this and other top news from Medicon Valley in the newsletter below.

Other news from the region are continuously updated on our webpage: www.mediconvalley.com/NewsAndEvents/News

  • BioInvent Signs Deal with Bayer HealthCare 25 Mar 2008

    BioInvent International AB has signed an agreement with Bayer Healthcare concerning the research and development of therapeutic antibodies. The agreement covers the development of up to 14 antibody pr...

  • CMC to Expand Under US Ownership 13 Mar 2008

    CMC Biologics A/S recently fetched EUR 25 million from a US capital fund which is to take over the leadership in the company from BankInvest. CMC Biologics will now have financial strength to consolid...

  • Genmab and Pepscan in Research Collaboration 4 Mar 2008

    Genmab A/S and Pepscan Therapeutics have announced the start of a research collaboration aimed at identifying fully human monoclonal antibodies against intractable disease targets. Intractable targets...

  • Microlytic is Ready to Launch its First Product 9 Apr 2008

    Danish fledgling firm Microlytic ApS is preparing to enter the equipment market for protein structure determination with a product called Crystal Maker at the "International Conference on the Crystall...

  • MycoTeq Raises Money for Development of New Antibiotics 9 Apr 2008

    Danish biotech company MycoTeq A/S has raised an undisclosed investment from Novo Seeds, DTU Innovation and Symbion. The money will be spent to continue and expand the search for new antibiotics, whic...

  • Upfront Chromatography in Development Agreement with Cangene Corporation 4 Mar 2008

    Upfront Chromatography A/S, the world's leading developer of customised industrial-scale protein chromatography processes, has entered into an agreement with Cangene Corporation to develop a high-...

  • Vaginal Probiotic Product Reduces Recurrence Rate of Bacterial Vaginosis 6 Feb 2008

    The Danish company Bifodan A/S has announced that a newly published double blind, randomised, placebo controlled study shows that EcoVag, a patented vaginal probiotic product, significantly reduces th...

Download as PDF: {57BAEA5D-138E-472D-A4D4-EB52A9397283}.pdf

Medicon Valley Biomedical Newsletter is published by Region Skåne and Copenhagen Capacity.

We assist foreign companies in finding locations and partnerships in Medicon Valley. We offer free assistance at each step of the business development phase. Visit www.mediconvalley.com or contact us to learn more about the opportunities that await your company in Medicon Valley.

Copenhagen Capacity
Email: info@copcap.com
Or visit: www.copcap.com

 

Region Skåne
Email: infonaringsliv@skane.se
Or visit: www.skane.com/invest

If you have any comments on the Medicon Valley Biomedical Newsletter please contact the editor at info@mediconvalley.com.

Here you can subscribe to the Medicon Valley Academy Newsletter
The MVA newsletter is an e-mail news service for Medicon Valley Academy (MVA) members and other actors within life science. The newsletter brings you information on new MVA initiatives and activities, editorials on issues of topical interest, news from the region together with available jobs and relevant life science events. Click here to subscribe or visit www.mva.org.

Home > News & Events > Medicon Valley Newsletter > April 2008
Last updated: 2008-04-16

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity, tel: +45 33 22 02 22
Region Skåne, tel: +46 (0)40 623 97 48